Cancer Immunology, Immunotherapy

, Volume 54, Issue 4, pp 297–306

Targeting the silent minority: emerging immunotherapeutic strategies for eradication of malignant stem cells in chronic myeloid leukaemia

  • M. Copland
  • A. R. Fraser
  • S. J. Harrison
  • T. L. Holyoake


Standard allogeneic stem cell transplantation (alloSCT) has provided a cure for chronic myeloid leukaemia (CML) over the last 25 years, but is only an option for a minority of patients. It was hoped that the introduction of imatinib mesylate (IM), a specific tyrosine kinase inhibitor that targets the Bcr-Abl oncogene product, would provide long-term remission or even cure for those patients without a donor, but studies have shown that IM does not eliminate leukaemic stem cells in CML patients. To overcome this problem of molecular persistence, research is underway to combine reduced intensity stem cell transplant or non-donor-dependent immunotherapies with IM with the aim of increasing cure rate, reducing toxicity and improving quality of life. The alternative approach is to combine IM or second-generation agents with other novel drugs that interrupt key signalling pathways activated by Bcr-Abl. This article will focus on the latest immunotherapy and molecularly targeted therapeutic options in CML and how they may be combined to improve the outcome for CML patients in the future.


Allogeneic stem cell transplantation Chronic myeloid leukaemia Cytotoxic T lymphocytes Dendritic cells Imatinib Immunotherapy 


  1. 1.
    Appel S, Boehmler AM, Grunebach F, Muller MR, Rupf A, Weck MM, Hartmann U, Reichardt VL, Kanz L, Brummendorf TH, Brossart P (2004) Imatinib mesylate affects the development and function of dendritic cells generated from CD34+ peripheral blood progenitor cells. Blood 103:538–544PubMedGoogle Scholar
  2. 2.
    Avery S, Nadal E, Davis J, Apperley J, Goldman J, Marin D (2003) Infusion of peripheral blood stem cells collected at diagnosis can improve the level of cytogenetic response in CML patients on imatinib whose treatment is limited by cytopaenia. Blood 102:318bGoogle Scholar
  3. 3.
    Bakalova R, Ohba H, Zhelev Z, Ishikawa M, Shinohara Y, Baba Y (2003) Cross-talk between Bcr-Abl tyrosine kinase, protein kinase C and telomerase-a potential reason for resistance to Glivec in chronic myelogenous leukaemia. Biochem Pharmacol 66:1879–1884PubMedGoogle Scholar
  4. 4.
    Banchereau J, Steinman RM (1998) Dendritic cells and the control of immunity. Nature 392:245–252CrossRefPubMedGoogle Scholar
  5. 5.
    Barrett AJ, van Rhee F (1997) Graft-versus-leukaemia. Baillieres Clin Haematol 10:337–355PubMedGoogle Scholar
  6. 6.
    Bedi A, Zehnbauer BA, Barber JP, Sharkis SJ, Jones RJ (1994) Inhibition of apoptosis by BCR-ABL in chronic myeloid leukaemia. Blood 83:2038–2044PubMedGoogle Scholar
  7. 7.
    Bellantuono I, Gao L, Parry S, Marley S, Dazzi F, Apperley J, Goldman JM, Stauss HJ (2002) Two distinct HLA-A0201-presented epitopes of the Wilms tumor antigen 1 can function as targets for leukemia-reactive CTL. Blood 100:3835–3837CrossRefPubMedGoogle Scholar
  8. 8.
    Berke Z, Andersen MH, Pedersen M, Fugger L, Zeuthen J, Haurum JS (2000) Peptides spanning the junctional region of both the abl/bcr and the bcr/abl fusion proteins bind common HLA class I molecules. Leukemia 14:419–426CrossRefPubMedGoogle Scholar
  9. 9.
    Bhatia R, Wayner EA, McGlave P, Verfaillie CM (1994) Interferon-alpha restores normal adhesion of chronic myelogenous leukaemia hematopoietic progenitors to bone marrow strom by correcting impaired beta 1 integrin receptor function. J Clin Invest 94:384–391PubMedGoogle Scholar
  10. 10.
    Bhatia R, Holtz M, Niu N, Gray R, Snyder DS, Sawyers CL, Arber DA, Slovak ML, Forman SJ (2003) Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood 101:4701–4707CrossRefPubMedGoogle Scholar
  11. 11.
    Bocchia M, Gentili S, Abruzzese E, Fanelli A, Iuliano F, Tabilio A, Amabile M, Forconi F, Pirrotta MT, Gozzetti A, Ippoliti M, Raspadori I, Lauria F (2003) Imatinib plus CMLVAX100 (p210 derived multipeptide vaccine): induction of complete molecular responses in patients with chronic myeloid leukaemia (CML) showing persistent residual disease during treatment with imatinib mesylate. Blood 102:30aGoogle Scholar
  12. 12.
    Brummendorf TH, Holyoake TL, Rufer N, Barnett MJ, Schulzer M, Eaves CJ, Eaves AC, Lansdorp PM (2000) Prognostic implications of differences in telomere length between normal and malignant cells from patients with chronic myeloid leukemia measured by flow cytometry. Blood 95:1883–1890PubMedGoogle Scholar
  13. 13.
    Buchdunger E, Zimmermann J, Mett H, Meyer T, Muller M, Druker BJ, Lydon NB (1996) Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 56:100–104PubMedGoogle Scholar
  14. 14.
    Burchert A, Wolfl S, Schmidt M, Brendel C, Denecke B, Cai D, Odyvanova L, Lahaye T, Muller MC, Berg T, Gschaidmeier H, Wittig B, Hehlmann R, Hochhaus A, Neubauer A (2003) Interferon-alpha, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia. Blood 101:259–264CrossRefPubMedGoogle Scholar
  15. 15.
    Burton CH, Avery S, Ranger A, Nadal E, Nathan I, Olavarria E, Apperley J, Goldman J (2003) Use of RT-PCR to monitor the possible benefit of adding interferon-alpha to imatinib for patients with CML in chronic phase. Blood 102:908aGoogle Scholar
  16. 16.
    Campbell JD, Cook G, Holyoake TL (2001) Evolution of bone marrow transplantation—the original immunotherapy. Trends Immunol 22:88–92CrossRefPubMedGoogle Scholar
  17. 17.
    Carter BZ, Schober WD, McQueen T, Andreeff M (2003) Reguation of survivin expression through bcr-abl/MAPK cascade: survivin as a therapeutic target in STI571 resistant CML cells. Blood 102:651aCrossRefGoogle Scholar
  18. 18.
    Cathcart K, Pinilla-Ibarz J, Korontsvit T, Schwartz J, Zakhaleva V, Papadopoulos EB, Scheinberg DA (2004) A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia. Blood 103:1037–1042CrossRefPubMedGoogle Scholar
  19. 19.
    Caux C, Massacrier C, Vanbervliet B, Dubois B, Durand I, Cella M, Lanzavecchia A, Banchereau J (1997) CD34+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to granulocyte-macrophage colony-stimulating factor plus tumor necrosis factor alpha, II: functional analysis. Blood 90:1458–1470PubMedGoogle Scholar
  20. 20.
    Cervantes F (2003) Durability of responses to imatinib in newly diagnosed chronic phase chronic myeloid leukaemia: 24 month update from the IRIS study. Blood 102:181aGoogle Scholar
  21. 21.
    Champlin R, Khouri I, Shimoni A, Gajewski J, Kornblau S, Molldrem J, Ueno N, Giralt S, Anderlini P (2000) Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy. Br J Haematol 111:18–29CrossRefPubMedGoogle Scholar
  22. 22.
    Choudhury A, Gajewski JL, Liang JC, Popat U, Claxton DF, Kliche KO, Andreeff M, Champlin RE (1997) Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome-positive chronic myelogenous leukemia. Blood 89:1133–1142PubMedGoogle Scholar
  23. 23.
    Clark RE, Dodi IA, Hill SC, Lill JR, Aubert G, Macintyre AR, Rojas J, Bourdon A, Bonner PL, Wang L, Christmas SE, Travers PJ, Creaser CS, Rees RC, Madrigal JA (2001) Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein. Blood 98:2887–2893CrossRefPubMedGoogle Scholar
  24. 24.
    Clift RA, Anasetti C (1997) Allografting for chronic myeloid leukaemia. Baillieres Clin Haematol 10:319–336PubMedGoogle Scholar
  25. 25.
    Daley GQ, Van Etten RA, Baltimore D (1990) Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 247:824–830PubMedGoogle Scholar
  26. 26.
    de Castro FA, Palma PV, Morais FR, Simoes BP, Carvalho PV, Ismael SJ, Lima CP, Voltarelli JC (2003) Immunological effects of interferon-alpha on chronic myelogenous leukemia. Leuk Lymphoma 44:2061–2067PubMedGoogle Scholar
  27. 27.
    Deininger MW, Goldman JM, Lydon N, Melo JV (1997) The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood 90:3691–3698PubMedGoogle Scholar
  28. 28.
    Dhodapkar MV, Steinman RM, Krasovsky J, Munz C, Bhardwaj N (2001) Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med 193:233–238CrossRefPubMedGoogle Scholar
  29. 29.
    Dietz AB, Souan L, Knutson GJ, Bulur PA, Litzow MR, Vuk-Pavlovic S (2004) Imatinib mesylate inhibits T cell proliferation in vitro and delayed-type hypersensitivity in vivo. Blood 104:1094–1099CrossRefPubMedGoogle Scholar
  30. 30.
    Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, Lydon NB (1996) Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2:561–566CrossRefPubMedGoogle Scholar
  31. 31.
    Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, Capdeville R, Talpaz M (2001) Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344:1038–1042CrossRefPubMedGoogle Scholar
  32. 32.
    Drummond MW, Holyoake TL (2001) Tyrosine kinase inhibitors in the treatment of chronic myeloid leukaemia: so far so good? Blood Rev 15:85–95CrossRefPubMedGoogle Scholar
  33. 33.
    Eaves AC, Cashman JD, Gaboury LA, Eaves CJ (1987) Clinical significance of long-term cultures of myeloid blood cells. Crit Rev Oncol Hematol 7:125–138PubMedGoogle Scholar
  34. 34.
    Eisendle K, Lang A, Eibl B, Nachbaur D, Glassl H, Fiegl M, Thaler J, Gastl G (2003) Phenotypic and functional deficiencies of leukaemic dendritic cells from patients with chronic myeloid leukaemia. Br J Haematol 120:63–73CrossRefPubMedGoogle Scholar
  35. 35.
    Feng L, Drummond MW, Byrne J, Shepherd PC, Apperley JF, O’Brien SG, Craddock C, Clark RE, Cervantes F, Lennard AL, Holyoake TL, Szydlo RM, Goldman JM, Kaeda JS (2002) Molecular monitoring of complete cytogenic responders following treatment with imatinib (STI571, Glivec) for CML: a report from the UKSTI571 study group. Blood 100:1425CrossRefPubMedGoogle Scholar
  36. 36.
    Gabriele L, Borghi P, Rozera C, Sestili P, Andreotti M, Guarini A, Montefusco E, Foa R, Belardelli F (2004) IFN-alpha promotes the rapid differentiation of monocytes from patients with chronic myeloid leukemia into activated dendritic cells tuned to undergo full maturation after LPS treatment. Blood 103:980–987CrossRefPubMedGoogle Scholar
  37. 37.
    Gale RP, Horowitz MM, Bortin MM (1989) IBMTR analysis of bone marrow transplants in acute leukaemia. Advisory Committee of the International Bone Marrow Transplant Registry (IBMTR). Bone Marrow Transplant 4[Suppl 3]:83–84Google Scholar
  38. 38.
    Gale RP, Horowitz MM, Ash RC, Champlin RE, Goldman JM, Rimm AA, Ringden O, Stone JA, Bortin MM (1994) Identical-twin bone marrow transplants for leukemia. Ann Intern Med 120:646–652PubMedGoogle Scholar
  39. 39.
    Gao L, Bellantuono I, Elsasser A, Marley SB, Gordon MY, Goldman JM, Stauss HJ (2000) Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood 95:2198–2203PubMedGoogle Scholar
  40. 40.
    Gao L, Xue SA, Hasserjian R, Cotter F, Kaeda J, Goldman JM, Dazzi F, Stauss HJ (2003) Human cytotoxic T lymphocytes specific for Wilms’ tumor antigen-1 inhibit engraftment of leukemia-initiating stem cells in non-obese diabetic-severe combined immunodeficient recipients. Transplantation 75:1429–1436CrossRefPubMedGoogle Scholar
  41. 41.
    Goldman JM, Gale RP, Horowitz MM, Biggs JC, Champlin RE, Gluckman E, Hoffmann RG, Jacobsen SJ, Marmont AM, McGlave PB et al (1988) Bone marrow transplantation for chronic myelogenous leukemia in chronic phase: increased risk for relapse associated with T-cell depletion. Ann Intern Med 108:806–814PubMedGoogle Scholar
  42. 42.
    Goodman M, Spector N, Rodrigues G, Cassileth PA (1998) Interleukin-2 therapy for advanced chronic myeloid leukemia. Leukemia 12:1682–1684CrossRefPubMedGoogle Scholar
  43. 43.
    Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, Sawyers CL (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293:876–880CrossRefPubMedGoogle Scholar
  44. 44.
    Graham SM, Jorgensen HG, Allan E, Pearson C, Alcorn MJ, Richmond L, Holyoake TL (2002) Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 99:319–325CrossRefPubMedGoogle Scholar
  45. 45.
    Graner MW, Zeng Y, Feng H, Katsanis E (2003) Tumor-derived chaperone-rich cell lysates are effective therapeutic vaccines against a variety of cancers. Cancer Immunol Immunother 52:226–234PubMedGoogle Scholar
  46. 46.
    Granucci F, Vizzardelli C, Pavelka N, Feau S, Persico M, Virzi E, Rescigno M, Moro G, Ricciardi-Castagnoli P (2001) Inducible IL-2 production by dendritic cells revealed by global gene expression analysis. Nat Immunol 2:882–888Google Scholar
  47. 47.
    Greiner J, Ringhoffer M, Taniguchi M, Schmitt A, Kirchner D, Krahn G, Heilmann V, Gschwend J, Bergmann L, Dohner H, Schmitt M (2002) Receptor for hyaluronan acid-mediated motility (RHAMM) is a new immunogenic leukemia-associated antigen in acute and chronic myeloid leukemia. Exp Hematol 30:1029–1035CrossRefPubMedGoogle Scholar
  48. 48.
    Greiner J, Ringhoffer M, Taniguchi M, Hauser T, Schmitt A, Dohner H, Schmitt M (2003) Characterization of several leukemia-associated antigens inducing humoral immune responses in acute and chronic myeloid leukemia. Int J Cancer 106:224–231CrossRefPubMedGoogle Scholar
  49. 49.
    Hahn EA, Glendenning GA, Sorensen MV, Hudgens SA, Druker BJ, Guilhot F, Larson RA, O’Brien SG, Dobrez DG, Hensley ML, Cella D (2003) Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study. J Clin Oncol 21:2138–2146CrossRefPubMedGoogle Scholar
  50. 50.
    Hochhaus A, Fischer T, Brummendorf TH, Schoch C, Muller MC, Merx K, Berger U, Gschaidmeier H, Hehlmann R (2002) Imatinib (Glivec) and pegylated interferon a2a (Pegasys) phase I/II combination study in chronic phase myelogenous leukaemia (CML). Blood 100:164aGoogle Scholar
  51. 51.
    Holyoake T, Jiang X, Eaves C, Eaves A (1999) Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia. Blood 94:2056–2064PubMedGoogle Scholar
  52. 52.
    Holyoake TL, Jiang X, Jorgensen HG, Graham S, Alcorn MJ, Laird C, Eaves AC, Eaves CJ (2001) Primitive quiescent leukemic cells from patients with chronic myeloid leukemia spontaneously initiate factor-independent growth in vitro in association with up-regulation of expression of interleukin-3. Blood 97:720–728CrossRefPubMedGoogle Scholar
  53. 53.
    Holyoake TL, Allan EK, Graham SJ, Godden JL, Mountford JC, Gilmour D, Richmond L, Jorgensen HG (2003) Combination therapies including imatinib do not eradicate quiescent chronic myeloid leukaemia stem cells in vitro. Blood 102:71aGoogle Scholar
  54. 54.
    Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ, Rimm AA, Ringden O, Rozman C, Speck B et al (1990) Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75:555–562PubMedGoogle Scholar
  55. 55.
    Hughes T, Branford S (2003) Molecular monitoring of chronic myeloid leukemia. Semin Hematol 40:62–68CrossRefPubMedGoogle Scholar
  56. 56.
    Hughes TP, Economou K, Mackinnon S, Vlitos M, Arthur CK, Guo AP, Rassool F, Apperley JF, Hows J, Goldman JM (1989) Slow evolution of chronic myeloid leukaemia relapsing after BMT with T-cell depleted donor marrow. Br J Haematol 73:462–467PubMedGoogle Scholar
  57. 57.
    Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML, Gathmann I, Bolton AE, van Hoomissen IC, Goldman JM, Radich JP (2003) Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 349:1423–1432CrossRefPubMedGoogle Scholar
  58. 58.
    Kloosterboer FM, van Luxemburg-Heijs SA, van Soest RA, Barbui AM, van Egmond HM, Strijbosch MP, Kester MG, Marijt WA, Goulmy E, Willemze R, Falkenburg JH (2004) Direct cloning of leukemia-reactive T cells from patients treated with donor lymphocyte infusion shows a relative dominance of hematopoiesis-restricted minor histocompatibility antigen HA-1 and HA-2 specific T cells. Leukemia 18:798–808CrossRefPubMedGoogle Scholar
  59. 59.
    Kolb HJ, Mittermuller J, Clemm C, Holler E, Ledderose G, Brehm G, Heim M, Wilmanns W (1990) Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 76:2462–2465PubMedGoogle Scholar
  60. 60.
    Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W, Ljungman P, Ferrant A, Verdonck L, Niederwieser D et al (1995) Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 86:2041–2050PubMedGoogle Scholar
  61. 61.
    le Coutre P, Mologni L, Cleris L, Marchesi E, Buchdunger E, Giardini R, Formelli F, Gambacorti-Passerini C (1999) In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor. J Natl Cancer Inst 91:163–168CrossRefPubMedGoogle Scholar
  62. 62.
    Li Z, Qiao Y, Laska E, Liu B, Glynn L, Kulko J, Bona RD, Gaffney J, Hegde UP, Moyo V, Srivastava PK (2003) Autologous heat shock protein 70-peptide complex as a vaccine for chronic myeloid leukaemia in chronic phase: an updated phase I study. Blood 102:911aGoogle Scholar
  63. 63.
    Mathe G, Amiel JL, Schwarzenberg L, Cattan A, Schneider M (1965) Adoptive immunotherapy of acute leukemia: experimental and clinical results. Cancer Res 25:1525–1531PubMedGoogle Scholar
  64. 64.
    Mauro MJ, O’Dwyer M, Stone RM, Walker T, Druker B (2002) Preliminary evaluation of the combination of imatinib mesylate (Gleevec) with low-dose Ara-C as initial therapy for newly diagnosed chronic phase CML. Blood 101:165aGoogle Scholar
  65. 65.
    Mohty M, Jarrossay D, Lafage-Pochitaloff M, Zandotti C, Briere F, de Lamballeri XN, Isnardon D, Sainty D, Olive D, Gaugler B (2001) Circulating blood dendritic cells from myeloid leukemia patients display quantitative and cytogenetic abnormalities as well as functional impairment. Blood 98:3750–3756CrossRefPubMedGoogle Scholar
  66. 66.
    Mohty M, Jourdan E, Ben Mami N, Vey N, Damaj G, Blaise D, Isnardon D, Olive D, Gaugler B (2004) Imatinib and plasmacytoid dendritic cell function in chronic myeloid leukemia patients. Blood 103:4666–4668CrossRefPubMedGoogle Scholar
  67. 67.
    Molldrem JJ, Lee PP, Wang C, Felio K, Kantarjian HM, Champlin RE, Davis MM (2000) Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med 6:1018–1023CrossRefPubMedGoogle Scholar
  68. 68.
    Morse MA, Lyerly HK, Li Y (1999) The role of IL-13 in the generation of dendritic cells in vitro. J Immunother 22:506–513Google Scholar
  69. 69.
    O’Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A, Hughes T, Lechner K, Nielsen JL, Rousselot P, Reiffers J, Saglio G, Shepherd J, Simonsson B, Gratwohl A, Goldman JM, Kantarjian H, Taylor K, Verhoef G, Bolton AE, Capdeville R, Druker BJ (2003) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348:994–1004CrossRefPubMedGoogle Scholar
  70. 70.
    O’Dwyer ME, Mauro MJ, Kuyl JM, Paquette R, Sawyers CL, Druker BJ (2001) Preliminary evaluation of the combination of imatinib mesylate (Gleevec) in combination with low dose interferon-alpha for the treatment of chronic phase CML. Blood 100:846aGoogle Scholar
  71. 71.
    Or R, Shapira MY, Resnick I, Amar A, Ackerstein A, Samuel S, Aker M, Naparstek E, Nagler A, Slavin S (2003) Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase. Blood 101:441–445CrossRefPubMedGoogle Scholar
  72. 72.
    Osman Y, Takahashi M, Zheng Z, Koike T, Toba K, Liu A, Furukawa T, Aoki S, Aizawa Y (1999) Generation of bcr-abl specific cytotoxic T-lymphocytes by using dendritic cells pulsed with bcr-abl (b3a2) peptide: its applicability for donor leukocyte transfusions in marrow grafted CML patients. Leukemia 13:166–174CrossRefPubMedGoogle Scholar
  73. 73.
    Osman Y, Takahashi M, Zheng Z, Toba K, Liu A, Furukawa T, Aizawa Y, Shibata A, Koike T (1999) Activation of autologous or HLA-identical sibling cytotoxic T lymphocytes by blood derived dendritic cells pulsed with tumor cell extracts. Oncol Rep 6:1057–1063PubMedGoogle Scholar
  74. 74.
    Ossenkoppele GJ, Stam AG, Westers TM, de Gruijl TD, Janssen JJ, van de Loosdrecht AA, Scheper RJ (2003) Vaccination of chronic myeloid leukemia patients with autologous in vitro cultured leukemic dendritic cells. Leukemia 17:1424–1426CrossRefPubMedGoogle Scholar
  75. 75.
    Pawelec G (2004) Tumour escape: antitumour effectors too much of a good thing? Cancer Immunol Immunother 53:262–274CrossRefPubMedGoogle Scholar
  76. 76.
    Pinilla-Ibarz J, Cathcart K, Korontsvit T, Soignet S, Bocchia M, Caggiano J, Lai L, Jimenez J, Kolitz J, Scheinberg DA (2000) Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses. Blood 95:1781–1787PubMedGoogle Scholar
  77. 77.
    Ridgway D (2003) The first 1000 dendritic cell vaccinees. Cancer Invest 21:873–886CrossRefPubMedGoogle Scholar
  78. 78.
    Rowley JD (1973) Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 243:290–293PubMedGoogle Scholar
  79. 79.
    Sallusto F, Lanzavecchia A (1994) Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 179:1109–1118CrossRefPubMedGoogle Scholar
  80. 80.
    Sato N, Narita M, Takahashi M, Yagisawa K, Liu A, Abe T, Nikkuni K, Furukawa T, Toba K, Aizawa Y (2003) The effects of STI571 on antigen presentation of dendritic cells generated from patients with chronic myelogenous leukemia. Hematol Oncol 21:67–75CrossRefPubMedGoogle Scholar
  81. 81.
    Sawyers CL (1999) Chronic myeloid leukemia. N Engl J Med 340:1330–1340CrossRefPubMedGoogle Scholar
  82. 82.
    Sawyers CL, Hochhaus A, Feldman E, Goldman JM, Miller CB, Ottmann OG, Schiffer CA, Talpaz M, Guilhot F, Deininger MW, Fischer T, O’Brien SG, Stone RM, Gambacorti-Passerini CB, Russell NH, Reiffers JJ, Shea TC, Chapuis B, Coutre S, Tura S, Morra E, Larson RA, Saven A, Peschel C, Gratwohl A, Mandelli F, Ben-Am M, Gathmann I, Capdeville R, Paquette RL, Druker BJ (2002) Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 99:3530–3539CrossRefPubMedGoogle Scholar
  83. 83.
    Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, Kuriyan J, Sawyers CL (2002) Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2:117–125CrossRefPubMedGoogle Scholar
  84. 84.
    Silver RT, Woolf SH, Hehlmann R, Appelbaum FR, Anderson J, Bennett C, Goldman JM, Guilhot F, Kantarjian HM, Lichtin AE, Talpaz M, Tura S (1999) An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American society of hematology. Blood 94:1517–1536PubMedGoogle Scholar
  85. 85.
    Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G, Varadi G, Kirschbaum M, Ackerstein A, Samuel S, Amar A, Brautbar C, Ben-Tal O, Eldor A, Or R (1998) Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 91:756–763PubMedGoogle Scholar
  86. 86.
    Spierings E, Wieles B, Goulmy E (2004) Minor histocompatibility antigens—big in tumour therapy. Trends Immunol 25:56–60CrossRefPubMedGoogle Scholar
  87. 87.
    Taieb J, Maruyama K, Borg C, Terme M, Zitvogel L (2004) Imatinib mesylate impairs Flt3L-mediated dendritic cell expansion and antitumor effects in vivo. Blood 103:1966–1967 (Author reply, 1967)CrossRefPubMedGoogle Scholar
  88. 88.
    Takahashi T, Tanaka Y, Nieda M, Azuma T, Chiba S, Juji T, Shibata Y, Hirai H (2003) Dendritic cell vaccination for patients with chronic myelogenous leukemia. Leuk Res 27:795–802CrossRefPubMedGoogle Scholar
  89. 89.
    Talpaz M, Silver RT, Druker BJ, Goldman JM, Gambacorti-Passerini C, Guilhot F, Schiffer CA, Fischer T, Deininger MW, Lennard AL, Hochhaus A, Ottmann OG, Gratwohl A, Baccarani M, Stone R, Tura S, Mahon FX, Fernandes-Reese S, Gathmann I, Capdeville R, Kantarjian HM, Sawyers CL (2002) Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 99:1928–1937CrossRefPubMedGoogle Scholar
  90. 90.
    Topaly J, Zeller WJ, Fruehauf S (2002) Combination therapy with imatinib mesylate (STI571): synopsis of in vitro studies. Br J Haematol 119:3–14CrossRefPubMedGoogle Scholar
  91. 91.
    Turtle CJ, Hart DN (2004) Dendritic cells in tumor immunology and immunotherapy. Curr Drug Targets 5:17–39PubMedGoogle Scholar
  92. 92.
    Vey N, Blaise D, Lafage M, Olive D, Viens P, Baume D, Camerlo J, Stoppa AM, Gabus R, Brandely M, Hercend T, Maraninchi D (1999) Treatment of chronic myelogenous leukemia with interleukin-2: a phase II study in 21 patients. J Immunother 22:175–181Google Scholar
  93. 93.
    Vivancos P, Granena A Jr, Sarra J, Granena A (1999) Treatment with interleukin-2 (IL-2) and interferon (IFN(alpha 2b)) after autologous bone marrow or peripheral blood stem cell transplantation in onco-hematological malignancies with a high risk of relapse. Bone Marrow Transplant 23:169–172CrossRefPubMedGoogle Scholar
  94. 94.
    Wang L, Butt NM, Atherton MG, Clark RE (2004) Dendritic cells become BCR-ABL negative in chronic myeloid leukaemia patients successfully treated with imatinib. Leukemia 18:1025–1027CrossRefPubMedGoogle Scholar
  95. 95.
    Wieder ED, Kant S, Lu S, He Z, Molldrem JJ (2003) PR1 peptide vaccination of myeloid leukaemia patients induces PR1-specific CTL with high CCR7 expression. Blood 102:611aGoogle Scholar
  96. 96.
    Zeis M, Siegel S, Wagner A, Schmitz M, Marget M, Kuhl-Burmeister R, Adamzik I, Kabelitz D, Dreger P, Schmitz N, Heiser A (2003) Generation of cytotoxic responses in mice and human individuals against hematological malignancies using survivin-RNA-transfected dendritic cells. J Immunol 170:5391–5397Google Scholar
  97. 97.
    Zeng Y, Graner MW, Feng H, Li G, Katsanis E (2004) Imatinib mesylate effectively combines with chaperone-rich cell lysate-loaded dendritic cells to treat bcr-abl+ murine leukemia. Int J Cancer 110:251–259CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2004

Authors and Affiliations

  • M. Copland
    • 1
  • A. R. Fraser
    • 1
  • S. J. Harrison
    • 1
  • T. L. Holyoake
    • 1
  1. 1.ATMU, Section of Experimental HaematologyUniversity Faculty of Medicine, Glasgow Royal InfirmaryGlasgowUK

Personalised recommendations